These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 23468534)

  • 1. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.
    Icardi A; Paoletti E; De Nicola L; Mazzaferro S; Russo R; Cozzolino M
    Nephrol Dial Transplant; 2013 Jul; 28(7):1672-9. PubMed ID: 23468534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of inflammation on renal anaemia].
    Icardi A; Sacco P; Tarroni A; Cappelletti L; Cozzolino M
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation.
    Macdougall IC; Cooper AC
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():32-5. PubMed ID: 16281956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Effect of Vitamin D Deficiency on Anemia and Erythropoietin Hyporesponsiveness in Patients of Chronic Kidney Disease.
    Nand N; Mittal R
    J Assoc Physicians India; 2017 Feb; 65(2):38-42. PubMed ID: 28457030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor activation and cardiovascular disease.
    Gonzalez-Parra E; Rojas-Rivera J; Tuñón J; Praga M; Ortiz A; Egido J
    Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv17-21. PubMed ID: 23258805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron Metabolism in Chronic Kidney Disease Patients.
    Honda H; Hosaka N; Ganz T; Shibata T
    Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agent hyporesponsiveness.
    Johnson DW; Pollock CA; Macdougall IC
    Nephrology (Carlton); 2007 Aug; 12(4):321-30. PubMed ID: 17635745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular mechanism of resistance to erythropoietin.
    Casadevall N
    Nephrol Dial Transplant; 1995; 10 Suppl 6():27-30. PubMed ID: 8524490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal anaemia: recent developments, innovative approaches and future directions for improved management.
    Kerr PG
    Nephrology (Carlton); 2006 Dec; 11(6):542-8. PubMed ID: 17199795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease.
    Kim IY; Kim JH; Kim MJ; Lee DW; Hwang CG; Han M; Rhee H; Song SH; Seong EY; Lee SB
    Int Urol Nephrol; 2018 Dec; 50(12):2255-2260. PubMed ID: 30136086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaemia, diabetes and chronic kidney disease: where are we now?
    Stevens PE
    J Ren Care; 2012 Feb; 38 Suppl 1():67-77. PubMed ID: 22348366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal anemia: from incurable to curable.
    Sato Y; Yanagita M
    Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1239-48. PubMed ID: 23884144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.